The SystHERs registry: an observational cohort study of treatment patterns and outcomes in patients with human epidermal growth factor receptor 2–positive metastatic breast cancer
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The SystHERs registry: an observational cohort study of treatment patterns and outcomes in patients with human epidermal growth factor receptor 2–positive metastatic breast cancer
Authors
Keywords
Ado-trastuzumab emtansine, Human epidermal growth factor receptor 2, HER2, Metastatic breast cancer, Observational cohort study, Patient-reported outcome, Pertuzumab, Registry, SystHERs, Trastuzumab, Trastuzumab emtansine
Journal
BMC CANCER
Volume 14, Issue 1, Pages -
Publisher
Springer Nature
Online
2014-05-02
DOI
10.1186/1471-2407-14-307
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Human Epidermal Growth Factor Receptor Family-Targeted Therapies in the Treatment of HER2-Overexpressing Breast Cancer
- (2014) Z. Eroglu et al. ONCOLOGIST
- Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study
- (2013) Sandra M Swain et al. LANCET ONCOLOGY
- First-Line Treatment Patterns and Clinical Outcomes in Patients With HER2-Positive and Hormone Receptor-Positive Metastatic Breast Cancer From registHER
- (2013) D. Tripathy et al. ONCOLOGIST
- Treatment patterns and clinical outcomes in elderly patients with HER2-positive metastatic breast cancer from the registHER observational study
- (2012) Peter A. Kaufman et al. BREAST CANCER RESEARCH AND TREATMENT
- New therapies in HER2-positive breast cancer: A major step towards a cure of the disease?
- (2012) Ahmad Awada et al. CANCER TREATMENT REVIEWS
- Current approaches and future directions in the treatment of HER2-positive breast cancer
- (2012) Sara A. Hurvitz et al. CANCER TREATMENT REVIEWS
- A Pooled Analysis of 2618 Patients Treated With Trastuzumab Beyond Progression for Advanced Breast Cancer
- (2012) Fausto Petrelli et al. Clinical Breast Cancer
- Recommendations for Incorporating Patient-Reported Outcomes Into Clinical Comparative Effectiveness Research in Adult Oncology
- (2012) Ethan Basch et al. JOURNAL OF CLINICAL ONCOLOGY
- Overall Survival Benefit With Lapatinib in Combination With Trastuzumab for Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer: Final Results From the EGF104900 Study
- (2012) Kimberly L. Blackwell et al. JOURNAL OF CLINICAL ONCOLOGY
- Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
- (2012) Sunil Verma et al. NEW ENGLAND JOURNAL OF MEDICINE
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- Central Nervous System Metastases in Patients with HER2-Positive Metastatic Breast Cancer: Incidence, Treatment, and Survival in Patients from registHER
- (2011) A. M. Brufsky et al. CLINICAL CANCER RESEARCH
- Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
- (2011) José Baselga et al. NEW ENGLAND JOURNAL OF MEDICINE
- Emerging Targeted Therapies for Breast Cancer
- (2010) Ricardo H. Alvarez et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Trial of Pertuzumab and Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer That Progressed During Prior Trastuzumab Therapy
- (2010) José Baselga et al. JOURNAL OF CLINICAL ONCOLOGY
- Trastuzumab Beyond Progression in Human Epidermal Growth Factor Receptor 2–Positive Advanced Breast Cancer: A German Breast Group 26/Breast International Group 03-05 Study
- (2009) Gunter von Minckwitz et al. JOURNAL OF CLINICAL ONCOLOGY
- Prognosis of Women With Metastatic Breast Cancer byHER2Status and Trastuzumab Treatment: An Institutional-Based Review
- (2009) Shaheenah Dawood et al. JOURNAL OF CLINICAL ONCOLOGY
- Molecular predictors of response to trastuzumab and lapatinib in breast cancer
- (2009) Francisco J. Esteva et al. Nature Reviews Clinical Oncology
- The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti-HER-2 Therapy and Personalized Medicine
- (2009) J. S. Ross et al. ONCOLOGIST
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started